In glioma, recent research demonstrates that the long non-coding RNA PVT1 oncogene enhances stemness and resistance to temozolomide (TMZ) in glioma through the miR-365/ELF4/SRY-Box Transcription Factor 2 (SOX2) pathway12. The gene discussed is ELF4; the disease is central nervous system cancer.